TXK tyrosine kinase | Tec family | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

TXK tyrosine kinase

Target id: 2268

Nomenclature: TXK tyrosine kinase

Abbreviated Name: TXK

Family: Tec family

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

   GtoImmuPdb view: ON :     TXK tyrosine kinase has curated data in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 527 4p12 TXK TXK tyrosine kinase
Mouse - 527 5 C3.2 Txk TXK tyrosine kinase
Rat - 526 14 p11 Txk TXK tyrosine kinase
Previous and Unofficial Names
BTKL | PSCTK5 | PTK4 protein tyrosine kinase 4 | RLK | TKL
Database Links
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
RefSeq Nucleotide
RefSeq Protein
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Solution structure of the SH2 domain of human tyrosine-protein kinase TXK.
PDB Id:  2DM0
Resolution:  0.0Å
Species:  Human
Enzyme Reaction
EC Number:

Download all structure-activity data for this target as a CSV file

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
bosutinib Hs Inhibition 9.5 pIC50 10
pIC50 9.5 (IC50 3x10-10 M) [10]
compound 23 [PMID: 17600705] Hs Inhibition 9.4 pIC50 2
pIC50 9.4 (IC50 4x10-10 M) [2]
compound 38 [PMID: 24915291] Hs Inhibition 8.9 pIC50 8
pIC50 8.9 (IC50 1.4x10-9 M) [8]
PRN694 Hs Inhibition 8.9 pIC50 12
pIC50 8.9 (IC50 1.4x10-9 M) [12]
compound 31 [PMID: 24915291] Hs Inhibition 8.7 pIC50 8
pIC50 8.7 (IC50 1.9x10-9 M) [8]
ibrutinib Hs Inhibition 8.7 pIC50 5
pIC50 8.7 (IC50 2x10-9 M) [5]
compound 9 [PMID: 26006010] Hs Inhibition 7.4 pIC50 4
pIC50 7.4 (IC50 4.1x10-8 M) [4]
compound 7 [PMID: 22464456] Hs Inhibition 7.1 pIC50 9
pIC50 7.1 (IC50 7.75x10-8 M) [9]
acalabrutinib Hs Inhibition 6.4 pIC50 5
pIC50 6.4 (IC50 3.68x10-7 M) [5]
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
Reference: 6,11

Key to terms and symbols Click column headers to sort
Target used in screen: TXK
Ligand Sp. Type Action Affinity Units
dasatinib Hs Inhibitor Inhibition 8.7 pKd
PD-173955 Hs Inhibitor Inhibition 7.5 pKd
bosutinib Hs Inhibitor Inhibition 7.1 pKd
tamatinib Hs Inhibitor Inhibition 6.8 pKd
staurosporine Hs Inhibitor Inhibition 6.6 pKd
PP-242 Hs Inhibitor Inhibition 6.5 pKd
NVP-TAE684 Hs Inhibitor Inhibition 6.3 pKd
foretinib Hs Inhibitor Inhibition 6.3 pKd
KW-2449 Hs Inhibitor Inhibition 6.2 pKd
lestaurtinib Hs Inhibitor Inhibition 6.2 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.


Reference: 1,7

Key to terms and symbols Click column headers to sort
Target used in screen: Txk/TXK
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
dasatinib Hs Inhibitor Inhibition 1.4
EGFR/ErbB-2/ErbB-4 inhibitor Hs Inhibitor Inhibition 1.7 52.0 14.0
Gö 6976 Hs Inhibitor Inhibition 6.4 8.0 8.0
staurosporine Hs Inhibitor Inhibition 7.3 22.5 4.0
Lck inhibitor Hs Inhibitor Inhibition 17.3 18.0 1.0
SB 218078 Hs Inhibitor Inhibition 22.7 71.0 81.0
K-252a Hs Inhibitor Inhibition 24.4 35.0 5.0
TWS119 Hs Inhibitor Inhibition 24.5 27.0 3.0
indirubin derivative E804 Hs Inhibitor Inhibition 25.6 31.0 3.0
bosutinib Hs Inhibitor Inhibition 27.5
Displaying the top 10 most potent ligands  View all ligands in screen »


Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1039-45. [PMID:22037377]

2. Bamborough P, Angell RM, Bhamra I, Brown D, Bull J, Christopher JA, Cooper AW, Fazal LH, Giordano I, Hind L et al.. (2007) N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg. Med. Chem. Lett., 17 (15): 4363-8. [PMID:17600705]

3. Berg LJ, Finkelstein LD, Lucas JA, Schwartzberg PL. (2005) Tec family kinases in T lymphocyte development and function. Annu. Rev. Immunol., 23: 549-600. [PMID:15771581]

4. Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phan VT, Romanov S, Finkle D, Shu J, Patel V et al.. (2015) Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat. Chem. Biol., 11 (7): 525-31. [PMID:26006010]

5. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR et al.. (2016) Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med., 374 (4): 323-32. [PMID:26641137]

6. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 29 (11): 1046-51. [PMID:22037378]

7. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J., 451 (2): 313-28. [PMID:23398362]

8. Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N, Pan Z. (2014) Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J. Med. Chem., 57 (12): 5112-28. [PMID:24915291]

9. McLean LR, Zhang Y, Zaidi N, Bi X, Wang R, Dharanipragada R, Jurcak JG, Gillespy TA, Zhao Z, Musick KY et al.. (2012) X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase. Bioorg. Med. Chem. Lett., 22 (9): 3296-300. [PMID:22464456]

10. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M et al.. (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia, 23 (3): 477-85. [PMID:19039322]

11. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol., 17 (11): 1241-9. [PMID:21095574]

12. Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A et al.. (2015) Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694. J. Biol. Chem., 290 (10): 5960-78. [PMID:25593320]

How to cite this page

Tec family: TXK tyrosine kinase. Last modified on 16/01/2018. Accessed on 20/01/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2268.